Xencor Future Growth

Future criteria checks 2/6

Xencor is forecast to grow earnings and revenue by 22.2% and 22.3% per annum respectively. EPS is expected to grow by 22.8% per annum. Return on equity is forecast to be -30.9% in 3 years.

Key information

22.2%

Earnings growth rate

22.8%

EPS growth rate

Biotechs earnings growth	20.7%
Revenue growth rate	22.3%
Future return on equity	-30.9%
Analyst coverage	Good
Last updated	15 Apr 2024

Recent future growth updates

Recent updates

Is Xencor (NASDAQ:XNCR) Weighed On By Its Debt Load?

Mar 27

There's No Escaping Xencor, Inc.'s (NASDAQ:XNCR) Muted Revenues Despite A 29% Share Price Rise

Feb 27

Party Time: Brokers Just Made Major Increases To Their Xencor, Inc. (NASDAQ:XNCR) Earnings Forecasts

Aug 08

Xencor, Inc.'s (NASDAQ:XNCR) Shares May Have Run Too Fast Too Soon

Aug 12

Xencor GAAP EPS of -$0.57 misses by $0.10, revenue of $30.18M misses by $3.83M

Aug 03

Xencor: Capital-Efficient Platform Tech Play With A Lot Going On

Jun 03

Xencor, Inc. (NASDAQ:XNCR) Shares Could Be 35% Above Their Intrinsic Value Estimate

Feb 18

Upgrade: Analysts Just Made A Huge Increase To Their Xencor, Inc. (NASDAQ:XNCR) Forecasts

Aug 06

It's Unlikely That The CEO Of Xencor, Inc. (NASDAQ:XNCR) Will See A Huge Pay Rise This Year

Jun 20

Party Time: Brokers Just Made Major Increases To Their Xencor, Inc. (NASDAQ:XNCR) Earnings Forecasts

Apr 02

Don't Ignore The Fact That This Insider Just Sold Some Shares In Xencor, Inc. (NASDAQ:XNCR)

Mar 06

Time To Worry? Analysts Are Downgrading Their Xencor, Inc. (NASDAQ:XNCR) Outlook

Mar 02

Are Investors Undervaluing Xencor, Inc. (NASDAQ:XNCR) By 39%?

Feb 26

Earnings and Revenue Growth Forecasts

NasdaqGM:XNCR - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	266	-100	N/A	N/A	5
12/31/2025	156	-171	-213	-180	11
12/31/2024	93	-204	-213	-171	12
12/31/2023	168	-126	64	85	N/A
9/30/2023	145	-119	-151	-121	N/A
6/30/2023	113	-128	-136	-94	N/A
3/31/2023	98	-140	-64	-12	N/A
12/31/2022	165	-55	-19	24	N/A
9/30/2022	297	30	72	111	N/A
6/30/2022	289	22	45	73	N/A
3/31/2022	327	109	2	19	N/A
12/31/2021	275	83	-33	-17	N/A
9/30/2021	163	-4	-75	-62	N/A
6/30/2021	179	24	-42	-26	N/A
3/31/2021	124	-64	-58	-44	N/A
12/31/2020	123	-69	-19	-5	N/A
9/30/2020	84	-83	-55	-42	N/A
6/30/2020	71	-80	-55	-44	N/A
3/31/2020	77	-61	80	93	N/A
12/31/2019	157	27	53	64	N/A
9/30/2019	165	36	56	67	N/A
6/30/2019	172	49	54	63	N/A
3/31/2019	153	39	-82	-74	N/A
12/31/2018	41	-70	-89	-80	N/A
9/30/2018	59	-45	-77	-70	N/A
6/30/2018	30	-71	-72	-63	N/A
3/31/2018	43	-53	-56	-47	N/A
12/31/2017	46	-38	-41	-34	N/A
9/30/2017	22	-55	N/A	-43	N/A
6/30/2017	30	-40	N/A	95	N/A
3/31/2017	84	15	N/A	98	N/A
12/31/2016	109	45	N/A	95	N/A
9/30/2016	103	40	N/A	107	N/A
6/30/2016	99	38	N/A	12	N/A
3/31/2016	34	-18	N/A	14	N/A
12/31/2015	28	-18	N/A	27	N/A
9/30/2015	12	-27	N/A	25	N/A
6/30/2015	9	-23	N/A	-20	N/A
3/31/2015	9	-19	N/A	-18	N/A
12/31/2014	10	-16	N/A	-21	N/A
9/30/2014	6	-19	N/A	-20	N/A
6/30/2014	8	-17	N/A	-19	N/A
3/31/2014	11	85	N/A	-12	N/A
12/31/2013	10	85	N/A	-5	N/A
9/30/2013	11	85	N/A	-5	N/A
6/30/2013	9	87	N/A	-4	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: XNCR is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: XNCR is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: XNCR is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: XNCR's revenue (22.3% per year) is forecast to grow faster than the US market (8.1% per year).

High Growth Revenue: XNCR's revenue (22.3% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: XNCR is forecast to be unprofitable in 3 years.

Discover growth companies

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Xencor Future Growth

Future criteria checks 2/6

Key information

Recent future growth updates

Consensus EPS estimates upgraded to US$1.66 loss

Consensus revenue estimates increase by 52%

Price target decreased by 7.0% to US$40.50

Consensus revenue estimates increase by 19%

Consensus EPS estimates fall by 20%

Consensus revenue estimates decrease by 13%

Recent updates

Xencor Appoints Bart Cornelissen as Senior Vice President

Is Xencor (NASDAQ:XNCR) Weighed On By Its Debt Load?

Co-Founder recently sold US$294k worth of stock

Co-Founder notifies of intention to sell stock

Full year 2023 earnings: EPS and revenues miss analyst expectations

There's No Escaping Xencor, Inc.'s (NASDAQ:XNCR) Muted Revenues Despite A 29% Share Price Rise

Xencor, Inc. to Report Q4, 2023 Results on Feb 27, 2024

Insider notifies of intention to sell stock

Xencor: Standing Out With XmAb Technology

Xencor, Inc.'s (NASDAQ:XNCR) Business And Shares Still Trailing The Industry

Xencor, Inc. Appoints Dane Leone as Senior Vice President, Corporate Strategy

Co-Founder notifies of intention to sell stock

Consensus EPS estimates upgraded to US$1.66 loss

Consensus revenue estimates increase by 52%

Xencor, Inc. (NASDAQ:XNCR) Analysts Just Cut Their EPS Forecasts Substantially

Companies Like Xencor (NASDAQ:XNCR) Are In A Position To Invest In Growth

Price target decreased by 7.0% to US$40.50

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Xencor, Inc. to Report Q3, 2023 Results on Nov 07, 2023

John J. Kuch to Retire as Chief Financial Officer of Xencor, Inc. in March 2024

Xencor, Inc. Appoints Barbara J. Klencke to Board of Directors

Consensus revenue estimates increase by 19%

Party Time: Brokers Just Made Major Increases To Their Xencor, Inc. (NASDAQ:XNCR) Earnings Forecasts

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Xencor, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Co-Founder notifies of intention to sell stock

Xencor, Inc. Presents Clinical Results from Phase 1a Study of XmAb®564 at the EULAR 2023 Congress

Consensus EPS estimates fall by 20%

Insufficient new directors

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Co-Founder recently sold US$183k worth of stock

Consensus revenue estimates decrease by 13%

Full year 2022 earnings: EPS exceeds analyst expectations

Xencor, Inc. to Report Q4, 2022 Results on Feb 23, 2023

Investor sentiment improves as stock rises 15%

Senior VP & Chief Medical Officer recently sold US$101k worth of stock

Senior VP & Chief Medical Officer notifies of intention to sell stock

Xencor, Inc. Presents Data from Phase 1 Study of Plamotamab in Relapsed or Refractory Non-Hodgkin Lymphoma At the American Society of Hematology Annual Meeting

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Xencor’s IL2-Fc Cytokine, XmAb®564, is Well-tolerated and Selectively Expands Regulatory T Cells in Phase 1a Clinical Study

Xencor, Inc. to Report Q3, 2022 Results on Nov 07, 2022

High number of new directors

Xencor, Inc. to Present Seven Posters on Multiple Clinical Trials and Research-Stage Programs At the SITC Annual Meeting

High number of new directors

Xencbor, Inc. Announces the Appointment of Nancy Valente to Its Board of Directors

Xencor, Inc.'s (NASDAQ:XNCR) Shares May Have Run Too Fast Too Soon

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Xencor GAAP EPS of -$0.57 misses by $0.10, revenue of $30.18M misses by $3.83M

Xencor, Inc. to Report Q2, 2022 Results on Aug 03, 2022

Investor sentiment improved over the past week

Xencor, Inc.(NasdaqGM:XNCR) dropped from Russell 2000 Growth-Defensive Index

Investor sentiment improved over the past week

Xencor: Capital-Efficient Platform Tech Play With A Lot Going On

Xencor, Inc. Reports Initial Dose-Escalation Data from Phase 1 Study of XmAb®104, PD-1 x ICOS Bispecific Antibody, in Advanced Solid Tumors

Price target decreased to US$50.13

Consensus revenue estimates increase by 40%

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Co-Founder recently sold US$72k worth of stock

Co-Founder notifies of intention to sell stock

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Consensus forecasts updated

Xencor, Inc. (NASDAQ:XNCR) Shares Could Be 35% Above Their Intrinsic Value Estimate

Xencor, Inc. to Report Q4, 2021 Results on Feb 23, 2022

Consensus EPS estimates increase by 52%

Consensus EPS estimates increase by 32%

Senior VP & Chief Medical Officer notifies of intention to sell stock

Xencor Presents Data from Phase 1 Study of Plamotamab in B-cell Non-Hodgkin Lymphomas at the ASH Annual Meeting

Zenas BioPharma Limited acquired Exclusive worldwide rights to Obexelimab from Xencor, Inc. (NasdaqGM:XNCR).

Third quarter 2021 earnings released: US$0.69 loss per share (vs US$0.22 loss in 3Q 2020)